Quantigen
Quantigen is a contract research organization and diagnostic laboratory specializing in sample-to-answer assay development, companion diagnostics, and molecular diagnostics for pharmaceutical, biotech, IVD, and academic clients. Founded in 2008, it operates from a 40,000 sq ft ISO 15189-accredited facility in Fishers, Indiana, and was acquired by Versiti Clinical Trial Services in July 2023.
- Company typePrivate
- Founded2008
- HeadquartersFishers, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Quantigen does
Quantigen Biosciences is a contract research organization and patient diagnostic laboratory founded in 2008 and headquartered in a 40,000-square-foot high-throughput facility in Fishers, Indiana. The company specializes in sample-to-answer method development and validation across three core application areas: Basic and Preclinical Research, Clinical and Translational Research, and Clinical Diagnostics. Its service portfolio spans biomarker and assay development including HLA typing, companion diagnostic (CDx) assay development, molecular diagnostics and infectious disease testing, clinical trial management, central laboratory services, and quality and regulatory services. The underlying technology leverages molecular biology, biotechnology, and regulatory oversight expertise to design customized, cost-effective workflows, supported by ISO 15189 accreditation.
Quantigen generates revenue through project-based contract research and assay development engagements sold directly to pharmaceutical and biotechnology companies, academic and institutional researchers, IVD developers, and medical device manufacturers. Pricing is not publicly disclosed and is typically quoted based on project scope. The company operates within a horizontal segmentation model, with therapeutic developers as the primary customer segment. Geographic reach is concentrated in the Midwest United States, with operations anchored in the Fishers, Indiana life sciences cluster.
In July 2023, Quantigen was acquired by Versiti Clinical Trial Services, a 501(c)(3) nonprofit organization, and was integrated into a unified platform alongside Pearl IRB, Salus IRB, Cenetron, and Pearl Pathways. The standalone Quantigen and Pearl Pathways websites were retired as part of the consolidation. Operating headcount is reported at 11-50 employees, and the company is now wholly owned by Versiti with no disclosed outside institutional or private equity investors.
Quantigen firmographics
Firmographics- Name
- Quantigen
- Legal name
- Quantigen Biosciences
- Website
- https://quantigen.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Quantigen is a contract research organization and diagnostic laboratory specializing in sample-to-answer assay development, companion diagnostics, and molecular diagnostics for pharmaceutical, biotech, IVD, and academic clients. Founded in 2008, it operates from a 40,000 sq ft ISO 15189-accredited facility in Fishers, Indiana, and was acquired by Versiti Clinical Trial Services in July 2023.
- Ownership category
- akta.pro rank
Quantigen industry classification
Industry- Product category
- Contract Research and Diagnostic Laboratory Services
- NAICS
- Medical Laboratories (621511), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
- akta.pro secondary industries
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Companion Diagnostics (CDx) & Precision Medicine IVD (HLAHAAAJ), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
Keywords
Where Quantigen is headquartered
LocationHeadquarters
- HQ city
- Fishers
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Quantigen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Distribution channels2 records
Marketing channels3 records
Quantigen product offering
Product offeringCore offering
Quantigen is a contract research organization and diagnostic laboratory that delivers sample-to-answer method development and validation across biomarker assay design, HLA typing, companion diagnostics, molecular diagnostics and infectious disease testing. The company operates a 40,000-square-foot ISO 15189-accredited high-throughput facility in Fishers, Indiana, serving pharmaceutical, biotechnology, IVD developer, medical device and academic clients through three core capability areas: Basic and Preclinical Research, Clinical and Translational Research, and Clinical Diagnostics.
Product overview
Quantigen operates as a high-throughput contract research and assay development organization offering integrated scientific services within the Versiti Clinical Trial Services family. Founded in 2008 and acquired by Versiti in July 2023, Quantigen specializes in sample-to-answer method development and validation across three core areas: Basic and Preclinical Research, Clinical and Translational Research, and Clinical Diagnostics. The product portfolio comprises six interconnected service offerings—Biomarker/Assay Development & HLA Typing, Companion Diagnostics, Molecular Diagnostics & Infectious Disease Testing, Clinical Trial Management, Laboratory & Diagnostic Services, and Quality & Regulatory Services—all designed to accelerate diagnostic innovation from discovery through deployment. These services are delivered from a 40,000-square-foot facility in Fishers, Indiana, and leverage expertise in molecular biology, biotechnology, and regulatory oversight to design customized, cost-effective workflows for clients.
Differentiator
Problem solved
Functional benefit
Products and services
- Biomarker, Assay Development & HLA Typing
Companies that use Quantigen
Customer profileSegments4 records
Ideal customer profiles3 records
Quantigen technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Quantigen partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Versiti Clinical Trial ServicescoreIn July 2023, Quantigen joined the Versiti Clinical Trial Services family, expanding its reach and integrating its robust capabilities within a broader clinical trials ecosystem. Quantigen became part of Versiti's portfolio of clinical trial services brands including Pearl IRB, Salus IRB, Cenetron, and Pearl Pathways, operating under a unified Versiti Clinical Trial Services platform.
Scale indicators3 records
Recent moves4 records
Expansion highlights3 records
Quantigen competitors and assessment
Company assessmentDirect peers
- BioAgilytix Labs: Specialty bioanalytical and biomarker CRO offering large-molecule bioanalysis, immunogenicity, cell-based assays, and biomarker services for pharma/biotech. Highly comparable to Quantigen's biomarker, assay development, and immunogenicity capabilities serving similar therapeutic developers.
- Eurofins Central Laboratory: Global central laboratory services for clinical trials, including biomarker analysis, specialty immunology, and molecular diagnostics. Directly comparable to Quantigen's central lab and clinical diagnostics service line within a CRO/trial-support framework.
- Q² Solutions (IQVIA/Quest Joint Venture): Central and specialty laboratory services for clinical trials spanning genomics, biomarkers, flow cytometry, and anatomic pathology. Closely aligned with Quantigen's molecular diagnostics, biomarker, and HLA/immunogenetics offerings for trial sponsors.
- ICON Central Laboratories: Provides central laboratory and biomarker services for global clinical trials, with capabilities in immunoassays, flow cytometry, and molecular diagnostics. Comparable to Quantigen's central lab role for therapeutic development programs.
- NeoGenomics Laboratories: Specialty oncology and molecular diagnostics laboratory providing clinical trial and CDx services to pharma/biotech. Comparable to Quantigen's molecular diagnostics, oncology focus, and CDx development capabilities.
- Frontage Laboratories: Contract research organization offering bioanalytical, biomarker, and CMC services to pharma and biotech. Comparable to Quantigen in providing regulated assay development and validation for therapeutic development.
Broad incumbents
- Labcorp (Fortrea) Clinical Development & Central Labs: Large CRO and central lab operator (post-Fortrea spin) with broad biomarker, CDx, and central lab capabilities. Comparable in service scope but materially larger and globally distributed than Quantigen.
- IQVIA Laboratories: Global CRO and central/biomarker laboratory serving pharmaceutical R&D and clinical trials across the full lifecycle. Comparable category (CRO + central lab) but operates at vastly greater scale and geographic reach.
- Charles River Laboratories: Large CRO with discovery, safety assessment, and CDx/biomarker service lines. Overlaps with Quantigen's biomarker and CDx work but operates as a broad incumbent with a much larger portfolio.
Regional players
- BARC Global Central Laboratory: Central laboratory serving European-based clinical trials with biomarker and specialty testing. Comparable central lab services to Quantigen but primarily European geography, providing an indirect competitive benchmark.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Quantigen social profiles
Digital presenceQuantigen compliance and trust
Trust signalCompliance1 record
Quantigen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quantigen leadership team
Management profileNumber of profiles
Quantigen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quantigen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quantigen
What does Quantigen do?
Quantigen is a contract research organization and diagnostic laboratory that delivers sample-to-answer method development and validation across biomarker assay design, HLA typing, companion diagnostics, molecular diagnostics and infectious disease testing. The company operates a 40,000-square-foot ISO 15189-accredited high-throughput facility in Fishers, Indiana, serving pharmaceutical, biotechnology, IVD developer, medical device and academic clients through three core capability areas: Basic and Preclinical Research, Clinical and Translational Research, and Clinical Diagnostics.
Is Quantigen a public or private company?
Quantigen is a private company. It is classified as nonprofit foundation owned and is currently acquired.
When was Quantigen founded?
Quantigen was founded in 2008. It employs 11 to 50 people.
Where is Quantigen based?
Quantigen is headquartered in Fishers, United States, in the North America region.
Who are Quantigen's main competitors?
Direct peers on record are BioAgilytix Labs, Eurofins Central Laboratory, Q² Solutions (IQVIA/Quest Joint Venture), ICON Central Laboratories, NeoGenomics Laboratories and Frontage Laboratories. Broad incumbents are Labcorp (Fortrea) Clinical Development & Central Labs, IQVIA Laboratories and Charles River Laboratories. BARC Global Central Laboratory is listed as a regional player.
Does Quantigen have an API?
No public API is recorded for Quantigen.
What industry is Quantigen in?
Quantigen's product category is Contract Research and Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 621511 and its SIC code is 8071.